TCGA-CN-5367-01A-01R-1436-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.080365297
- sex
- female
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V2+0.540
- E2F_TARGETS+0.410
- G2M_CHECKPOINT+0.360
- MYC_TARGETS_V1+0.350
- MYOGENESIS+0.290
- INTERFERON_ALPHA_RESPONSE+0.220
- KRAS_SIGNALING_DN+0.220
- COAGULATION+0.180
- SPERMATOGENESIS+0.160
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.150
Top 10 suppressed
- TNFA_SIGNALING_VIA_NFKB-0.390
- OXIDATIVE_PHOSPHORYLATION-0.370
- IL6_JAK_STAT3_SIGNALING-0.360
- CHOLESTEROL_HOMEOSTASIS-0.310
- PI3K_AKT_MTOR_SIGNALING-0.310
- ALLOGRAFT_REJECTION-0.290
- COMPLEMENT-0.260
- INFLAMMATORY_RESPONSE-0.260
- HYPOXIA-0.250
- MTORC1_SIGNALING-0.220
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR12475144 | — | — | 0.745 |
| 2 | TCGA-OR-A5JJ-01 | Adrenocortical Carcinoma | Adrenocortical Carcinoma, Usual Type | 0.742 |
| 3 | eb5ad680-6080-41fe-982e-e46f90c3849f | — | — | 0.720 |
| 4 | MNG305 | — | — | 0.717 |
| 5 | b985822b-8c9c-4e26-9f11-4f5dbe736518 | — | — | 0.716 |
| 6 | SRR4195683 | — | — | 0.716 |
| 7 | SRR4296090 | — | cohortMD1 | 0.715 |
| 8 | BSR_21_0015_A1_S76 | — | B | 0.711 |
| 9 | SRR10900589 | — | — | 0.703 |
| 10 | ba37d677-fb91-4aab-80a9-b2fd0bc39057 | — | — | 0.700 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 17 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V2 | 0.540 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.410 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.360 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.350 | Inavolisib | — uncovered |
| MYOGENESIS | 0.290 | Inavolisib | — uncovered |
| INTERFERON_ALPHA_RESPONSE | 0.220 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.220 | Remibrutinib | — uncovered |
| COAGULATION | 0.180 | Binimetinib | — uncovered |
| SPERMATOGENESIS | 0.160 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.150 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.150 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.110 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.060 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.050 | Temsirolimus | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.050 | Inavolisib | — uncovered |
| APICAL_JUNCTION | 0.030 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.030 | Inavolisib | — uncovered |